Logo
x

Search

Subscribe Now

Trastuzumab

Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Cancer

Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Ca...

  • February 2, 2022
Accord Launches Zercepac (biosimilar- trastuzumab) in the UK

Accord Launches Zercepac (biosimilar- trastuzumab) in the UK

  • September 25, 2020
Henlius Present P-III Data of HLX02 (biosimilar- trastuzumab) at ESMO

Henlius Present P-III Data of HLX02 (biosimilar- trastuzumab) at ESMO

  • September 17, 2020
Henlius' HLX02 Receives the NMPA's Approval as the First Trastuzumab Biosimilar in China

Henlius' HLX02 Receives the NMPA's Approval as the First Trastuzumab Biosimilar in China

  • August 17, 2020
Samsung Bioepis Launches Ontruzant (trastuzumab- biosimilar) for Early and Metastatic HER2-Overexpressing Breast Cancer in Brazil

Samsung Bioepis Launches Ontruzant (trastuzumab- biosimilar) for Early and Metastatic HER2-Overexpressing Breast Cancer in Brazil

  • August 11, 2020
Insights+ Key Biosimilars Events of May 2020

Insights+ Key Biosimilars Events of May 2020

  • June 5, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.